ANTERO-5: Gastric Motility in Postoperative Ileus (ANTERO-5)

ANTERO-5: A Clinical Investigation of Gastric Motility in Adult Patients at Risk to Develop Postoperative Ileus Following Colorectal Surgery

A monocenter, non-randomized interventional investigation in 3 panels of adult patients undergoing elective colorectal surgery who are at risk to develop postoperative ileus.

The feasibility to use the VIPUN Gastric Monitoring System prototype 0.3 will be explored in this population for the first time.

Study Overview

• Status: Terminated
• Conditions: Postoperative Ileus
• Intervention / Treatment: Device: Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System); Device: Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System)

• Study Type: Interventional
• Enrollment (Actual): 5
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Leuven, Belgium, 3000
    • UZ Leuven

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed Informed Consent
• At least 18 years old
• BMI between and including 18 and 30
• Understand and able to read Dutch
• Planned to undergo elective colorectal surgery

Exclusion Criteria:

• Known history of documented gastroparesis
• Known history of functional dyspepsia
• Known / suspected current use of illicit drugs
• Known psychiatric or neurological illness
• Any prior gastrointestinal surgery that could influence normal gastric function in the opinion of the investigator
• Known history of heart or vascular diseases like irregular heartbeats, angina or heart attack
• Nasopharyngeal surgery in the last 30 days
• Suspected basal skull fracture or severe maxillofacial trauma
• Known history of thermal or chemical injury to upper respiratory tract or esophagus
• Current esophageal or nasopharyngeal obstruction
• Known coagulopathy
• Known esophageal varices

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DEVICE_FEASIBILITY
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Panel 1 - High risk for postoperative ileus; Intervention in patients at high risk to develop prolonged postoperative ileus. Monitoring postoperative gastric motility for 2 consecutive days in patients who require preventive placement of a nasogastric feeding tube due to a high risk to develop postoperative ileus. Allowing to explore associations between gastric motility and general clinical evolution.	Device: Panel 1 - High risk for postoperative ileus (VIPUN Gastric Monitoring System); The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed during surgery.; Other Names: VIPUN Gastric Monitoring System prototype 0.3
EXPERIMENTAL: Panel 2 - Postoperative ileus arm with investigational device; Intervention in a population of patients with clinical signs of postoperative ileus, requiring a nasogastric feeding tube for symptom relief. The investigational medical device will be applied. Allowing to explore the association of gastric motility and clinical signs of postoperative ileus in an enriched population with true postoperative ileus.	Device: Panel 2 - Postoperative ileus arm with investigational device (VIPUN Gastric Monitoring System); The VIPUN Gastric Monitoring System prototype 0.3 comprises a nasogastric balloon catheter which is connected to an extracorporeal pressure sensor and data acquisition system. The device is placed upon the manifestation of clinical signs of postoperative ileus.; Other Names: VIPUN Gastric Monitoring System prototype 0.3
NO_INTERVENTION: Panel 3 - Postoperative ileus arm with standard of care; Standard of care control group of patients with clinical signs of postoperative ileus requiring a standard nasogastric feeding tube for symptom relief. Symptoms will be surveyed as control group to assess safety and tolerability of the investigational medical device.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility (composite endpoint)	Composite endpoint comprising: procedural success (absence of protocol deviations with regard to motility measurement), tolerability of the device (non-validated questionnaire on nasopharyngeal discomfort and the incidence of intolerance resulting in early removal of the investigational device) and device-related safety (incidence of adverse device effects related to the use of the device).	Day 1 - Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Gastric motility	Long term motility index	Day 1 until termination motility recording (maximum 48 hours)
Evolution postoperative ileus - staff reported	Incidence of markers of resolution of postoperative ileus (first flatus, bowel sounds, bowel movements, solid food tolerance)	Day 1 until completion study procedures (maximum 14 days).
In hospital quality of life (EQ-5D-3L questionnaire)	EQ-5D-3L questionnaire consists of 2 pages: EQ-5D descriptive system and an EQ visual analogue scale (EQ VAS). EQ-5D-3L (not an acronym) descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The five dimensions can be combined into a 5-digit number that describes the patient's health state. EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'.	Day 1 until completion study procedures (maximum 14 days)
Device performance	Incidence of device deficiencies	Day 1 until removal of device, no later than Day 14
Nausea severity	Patient reported severity of nausea (100 mm visual analogue scale ranging from Absent to Worst possible)	Day 1 until completion study procedures (maximum 14 days)
Abdominal bloating severity	Patient reported severity of abdominal bloating (100 mm visual analogue scale ranging from Absent to Worst possible)	Day 1 until completion study procedures (maximum 14 days)
Abdominal pain severity	Patient reported severity of abdominal pain (100 mm visual analogue scale ranging from Absent to Worst possible)	Day 1 until completion study procedures (maximum 14 days)
Abdominal discomfort severity	Patient reported severity of abdominal discomfort (100 mm visual analogue scale ranging from Absent to Worst possible)	Day 1 until completion study procedures (maximum 14 days)

Collaborators and Investigators

• Sponsor: Universitaire Ziekenhuizen KU Leuven

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 16, 2019
• Primary Completion (ACTUAL): January 21, 2021
• Study Completion (ACTUAL): January 21, 2021

Study Registration Dates

• First Submitted: September 11, 2019
• First Submitted That Met QC Criteria: September 23, 2019
• First Posted (ACTUAL): September 24, 2019

Study Record Updates

• Last Update Posted (ACTUAL): February 10, 2021
• Last Update Submitted That Met QC Criteria: February 5, 2021
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Intestinal Diseases; Intestinal Obstruction; Ileus
• Other Study ID Numbers: S63029

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No